Corticosteroid Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44

被引：0

作者：

Bressler, Brian ^{[1
]}

Allegretti, Jessica R. ^{[2
]}

Rubin, David T. ^{[3
]}

Shipitofsky, Nicole ^{[4
]}

Huang, Kuan-Hsiang G. ^{[4
]}

Germinaro, Matthew ^{[4
]}

Wilson, Rebbecca ^{[5
]}

Zhang, Hongyan ^{[4
]}

Armuzzi, Alessandro ^{[6
]}

Fishman, Sigal ^{[7
]}

Wang, Yufang ^{[8
]}

Panes, Julian ^{[9
]}

Lichtenstein, Gary R. ^{[10
]}

Peyrin-Biroulet, Laurent ^{[11
,12
]}

机构：

[1] Univ British Columbia, IBD Ctr BC, Vancouver, BC, Canada

[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[3] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA

[4] Janssen Res & Dev, Spring House, PA USA

[5] Janssen Res & Dev LLC, Spring House, PA USA

[6] IRCCS Humanitas Res Hosp, Milan, Italy

[7] Sourasky Med Ctr, Tel Aviv, Israel

[8] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China

[9] Hosp Clin Barcelona, CIBERehd, IDIBAPS, Barcelona, Catalonia, Spain

[10] Univ Penn, Perelman Ctr Adv Med, Philadelphia, PA USA

[11] Nancy Univ Hosp, INFINY Inst, FHU CURE, INSERM NGERE, Vandoeuvre Les Nancy, Lorraine, France

[12] McGill Univ Hlth Ctr, Montreal, PQ, Canada

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期

关键词：

D O I：

10.14309/01.ajg.0001034976.21441.52

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S1402

引用

页码：S1002 / S1002

页数：1

共 50 条

[31] EFFICACY AND SAFETY OF COMBINATION INDUCTION THERAPY WITH GUSELKUMAB AND GOLIMUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS THROUGH WEEK 12 OF THE PHASE 2A VEGA STUDY
Feagan, Brian G.
Sands, Bruce E.
Sandborn, William J.
Shipitofsky, Nicole
Marko, Melissa G.
Sheng, Shihong
Johanns, Jewel
Germinaro, Matthew
Vetter, Marion
Panes, Julian
GASTROENTEROLOGY, 2022, 162 (07) : S215 - S216
[32] The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced
Rubin, David T.
Allegretti, Jessica R.
Sands, Bruce E.
Huang, Kuan-Hsiang
Kavalam, Mary
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
Mihaly, Emese
Hisamatsu, Tadakazu
Dignass, Axel
Panes, Julian
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S500 - S501
[33] Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study
Loftus, Edward V., Jr.
Vermeire, Severine
Feagan, Brian G.
Le Brun, Franck-Olivier
Oortwijn, Alessandra
Moerch, Ulrik
Sandborn, William J.
Hibi, Toshifumi
JOURNAL OF CROHNS & COLITIS, 2023, 17 (02): : 211 - 220
[34] Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: Results through week 12 from the phase 3 ASTRO study
Peyrin-Biroulet, L.
Allegretti, J. R.
Danese, S.
Germinaro, M.
Baker, T.
Alvarez, Y.
Jorgens, S.
Jiang, L.
Zhang, H.
Hisamatsu, T.
Rubin, D. T.
Long, M.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i19 - i20
[35] Efficacy and Safety of Guselkumab Maintenance Therapy Among Guselkumab Induction Week 24 Clinical Responders: Results From the Phase 3 QUASAR Maintenance Study
Rubin, David T.
Dignass, Axel
Allegretti, Jessica R.
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Zhan, Jia
Zhang, Hongyan
Rayyan, Yaser
Saruta, Masayuki
Balderramo, Domingo
Bressler, Brian
Peyrin-Biroulet, Laurent
Hisamatsu, Tadakazu
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S744 - S745
[36] GUSELKUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY PROMIS-29 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY
Panes, Julian
Dignass, Axel
Lichtenstein, Gary R.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Houck, Nicole
Han, Chenglong
Miao, Ye
Zhang, Hongyan
Abu Farsakh, Niazy A.
Patel, Bhaktasharan
Owczarek, Danuta
Hisamatsu, Tadakazu
Sands, Bruce E.
Bressler, Brian
GASTROENTEROLOGY, 2024, 166 (05) : S848 - S848
[37] Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study
Panes, J.
Dignass, A.
Lichtenstein, G.
Huang, K. H.
Germinaro, M.
Houck, N.
Han, C.
Miao, Y.
Zhang, H.
Abu Farsakh, N.
Patel, B.
Owczarek, D.
Hisamatsu, T.
Sands, B.
Bressler, B.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I160 - I161
[38] MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Panes, J.
Rubin, D. T.
Vermeire, S.
Lindsay, J. O.
Sands, B. E.
Su, C.
Friedman, G.
Zhang, H.
Kayhan, C.
Manuchehri, A.
Healey, P.
GUT, 2017, 66 : A121 - A122
[39] MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Panes, Julian
Rubin, David T.
Vermeire, Severine
Lindsay, James O.
Sands, Bruce E.
Su, Chinyu
Friedman, Gary
Zhang, Haiying
Kayhan, Cem
Manuchehri, Alireza
Healey, Paul J.
GASTROENTEROLOGY, 2017, 152 (05) : S601 - S602
[40] Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis
Panes, J.
Rubin, D. T.
Vermeire, S.
Lindsay, J. O.
Sands, B. E.
JOURNAL OF CROHNS & COLITIS, 2017, 11 : S315 - S317

← 1 2 3 4 5 →